uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Haggård, Linnea
Publications (1 of 1) Show all publications
Haggård, L., Andersson, M. & Punga, A. R. (2013). beta-glucans reduce LDL cholesterol in patients with myasthenia gravis. European Journal of Clinical Nutrition, 67(2), 226-227
Open this publication in new window or tab >>beta-glucans reduce LDL cholesterol in patients with myasthenia gravis
2013 (English)In: European Journal of Clinical Nutrition, ISSN 0954-3007, E-ISSN 1476-5640, Vol. 67, no 2, p. 226-227Article in journal (Refereed) Published
Abstract [en]

We aimed at evaluating whether beta-glucans could improve low-density lipoprotein (LDL) cholesterol levels and/or glycemic control in patients with myasthenia gravis (MG), in whom statins usually have muscle-related side effects. Fifty-nine MG patients participated in the study and received a daily dietary supplement of 3 g of beta-glucans during 8 weeks. Body mass index (BMI) and blood sample analysis of lipid and glucose status were performed before and after 8 weeks intake of beta-glucans. In the 52 patients who completed the study, there was a significant reduction in total cholesterol, LDL, ApoA1 and ApoB (all P<0.003). However, glycemic control and BMI were unaltered. The present study indicates that 8 weeks daily intake of 3 g of beta-glucans significantly reduces total cholesterol, LDL, ApoA1 and ApoB in MG patients. beta-glucans may therefore be of value in improving lipid status in MG patients, without the muscle-related side effects accompanied by statins.

Keywords
beta-glucans, LDL cholesterol, myasthenia gravis, glycemic control
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-197408 (URN)10.1038/ejcn.2012.191 (DOI)000315016300018 ()
Available from: 2013-03-28 Created: 2013-03-25 Last updated: 2017-12-06Bibliographically approved
Organisations

Search in DiVA

Show all publications